Join the Mydayis group to help and get support from people like you.
Mydayis News
FDA Will Now Require Labeling of ADHD Medication to Indicate Weight Loss Risk
WEDNESDAY, July 2, 2025 – The U.S. Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity disorder (ADHD) medications, including certain...
ADHD Medications Remain Linked to Lower Risk for Real-World Adverse Outcomes
WEDNESDAY, July 2, 2025 – Attention-deficit/hyperactivity disorder (ADHD) medications remain associated with a reduced risk for various real-world outcomes, but the magnitude of these associations...
FDA Medwatch Alert: FDA Requires Expanded Labeling About Weight Loss Risk in Patients Younger Than 6 Years Taking Extended-Release Stimulants for ADHD
FDA Drug Safety Communication - June 30, 2025 What safety concern is FDA announcing?The U.S. Food and Drug Administration (FDA) is revising the labeling of all extended-release stimulants indicated...
Prescribing ADHD Meds by Telehealth Does Not Alter Risk for Substance Use Disorder Overall
TUESDAY, June 17, 2025 – Receipt of a stimulant prescription for attention-deficit/hyperactivity disorder (ADHD) via telehealth is not associated with an increased risk for substance use disorder...
Stimulant Dispensing to Children Decreased After Start of Pandemic, During Shortage
MONDAY, Jan. 27, 2025 – Stimulant dispensing to children aged 5 to 17 years decreased after the start of the COVID-19 pandemic and during a shortage of immediate-release mixed amphetamine salts in...
Rx Amphetamine Use Linked to Increased Odds of Psychosis, Mania
TUESDAY, Sept. 17, 2024 – Past-month prescription amphetamine use is associated with increased odds of psychosis and mania, with increased odds for high doses (>30 mg dextroamphetamine equivalents),...
FDA Medwatch Alert: FDA Updating Warnings to Improve Safe Use of Prescription Stimulants Used to Treat ADHD and Other Conditions
What safety concern is FDA announcing? To address continuing concerns of misuse, abuse, addiction, and overdose of prescription stimulants, the U.S. Food and Drug Administration (FDA) is requiring...
FDA Approves Mydayis (mixed salts of a single-entity amphetamine product) – A New Once-Daily Option for ADHD
Lexington, Mass., USA – June 20, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG) announced today that the U.S. Food and Drug Administration (FDA) has approved Mydayis (mixed salts of a single-entity amp...
Further information
Related condition support groups
Attention-Deficit Hyperactivity Disorder (ADHD)